Page last updated: 2024-08-17

levodopa and Encephalopathy, Toxic

levodopa has been researched along with Encephalopathy, Toxic in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (40.91)	29.6817
2010's	11 (50.00)	24.3611
2020's	2 (9.09)	2.80

Authors

Authors	Studies
Chen, H; Chen, J; Chen, S; Li, Q; Liu, J; Lu, Y; Shao, F; Tang, M; Wu, W; Xu, Z; Yang, D; Zhai, L	1
Dimitriou, A; Efthimiou, P; Karveli, M; Lagadinou, M; Skaltsa, M; Tsigkou, A; Velissaris, D; Zareifopoulos, N	1
Choi, H; Koh, SH	1
Choi, HS; Choi, SO; Kwon, IH; Lee, MK; Shin, KS; Suh, KH; Zhao, TT	1
Abboud, H; Lakhan, SE	1
Alharrasi, A; Ashraf, GM; Damanhouri, GA; Hadi, SM; Khan, HY; Perveen, A; Tabrez, S	1
Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L	1
Ben, J; de Oliveira, PA; Matheus, FC; Moreira, ELG; Prediger, RD; Rial, D; Schwarzbold, ML; Walz, R	1
Du, F; Ke, Y; Qian, ZM; Tsim, TY; Wu, XM; Yung, WH; Zhu, L	1
Francescutti-Verbeem, DM; Kuhn, DM; Thomas, DM	1
Kim, HT; Kim, SH; Koh, SH	1
Buck, K; Ferger, B; Voehringer, P	1
Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M	1
Jugel, C; Klostermann, F; Marzinzik, F; Müller, T	1
Barrow, R; Errico, F; Kim, S; Mealer, RG; Napolitano, F; Shahani, N; Snyder, SH; Subramaniam, S; Tyagi, R; Usiello, A	1
Nishijima, K; Saito, S; Shioda, K	1
Di Monte, DA; McCormack, AL; Miller, GW; Reveron, ME; Savelieva, KV; Tillerson, JL	1
Asanuma, M; Miyazaki, I; Ogawa, N	1
Ogawa, N; Tanaka, K	1
Kurlan, R	1
Weiss, B	1
Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB	1

Reviews

5 review(s) available for levodopa and Encephalopathy, Toxic

Article	Year
Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:13 Topics: Antipsychotic Agents; Dopamine; Dopaminergic Neurons; Humans; Levodopa; Methamphetamine; Mitochondria; Neurotoxicity Syndromes; Oxidation-Reduction; Oxidative Stress; Synaptic Transmission	2021
Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:1 Topics: Animals; Antiparkinson Agents; beta Catenin; Dopamine; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3; Humans; Levodopa; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease	2018
Role of glycogen synthase kinase-3 in l-DOPA-induced neurotoxicity. Expert opinion on drug metabolism & toxicology, 2009, Volume: 5, Issue:11 Topics: Animals; Antiparkinson Agents; Cell Death; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Levodopa; Neurons; Neurotoxicity Syndromes	2009
Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotoxicity research, 2003, Volume: 5, Issue:3 Topics: Animals; Dopamine; Dopamine Agents; Free Radicals; Humans; Levodopa; Monophenol Monooxygenase; Neurotoxicity Syndromes; Parkinson Disease	2003
Economic implications of manganese neurotoxicity. Neurotoxicology, 2006, Volume: 27, Issue:3 Topics: Adult; Age Factors; Aged; Animals; Female; Humans; Intelligence; Levodopa; Male; Manganese Poisoning; Middle Aged; Neural Pathways; Neurotoxicity Syndromes; Parkinson Disease; Risk Factors	2006

Other Studies

17 other study(ies) available for levodopa and Encephalopathy, Toxic

Article	Year
Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells. Marine drugs, 2022, Mar-31, Volume: 20, Issue:4 Topics: Animals; Antioxidants; Humans; Levodopa; Mice; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Xanthophylls	2022
Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Archives of pharmacal research, 2013, Volume: 36, Issue:6 Topics: Animals; Antiparkinson Agents; Berberine; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors	2013
Teaching neuroimages: manganese neurotoxicity of the basal ganglia and thalamus. Neurology, 2013, Oct-01, Volume: 81, Issue:14 Topics: Adult; Basal Ganglia; Chelation Therapy; Cholestasis; Dopamine Agents; Humans; Levodopa; Magnetic Resonance Imaging; Male; Manganese; Neuroimaging; Neurology; Neurotoxicity Syndromes; Thalamus	2013
Pro-oxidant DNA breakage induced by the interaction of L-DOPA with Cu(II): a putative mechanism of neurotoxicity. Advances in experimental medicine and biology, 2015, Volume: 822 Topics: Antiparkinson Agents; Chelating Agents; Comet Assay; Copper; DNA Breaks; Humans; Hydroxyl Radical; Levodopa; Lymphocytes; Neurotoxicity Syndromes; Oxidation-Reduction; Phenanthrolines; Reactive Oxygen Species; Superoxides	2015
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors. Experimental neurology, 2016, Volume: 277 Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus	2016
Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice. Brain research, 2017, 05-15, Volume: 1663 Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Brain Injuries; Brain Injuries, Traumatic; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Levodopa; Mice; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidopamine; Tyrosine 3-Monooxygenase	2017
L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PloS one, 2009, Volume: 4, Issue:2 Topics: Animals; Astrocytes; Cation Transport Proteins; Cells, Cultured; Cerebral Cortex; Culture Media, Conditioned; Dose-Response Relationship, Drug; Iron; Levodopa; Neurons; Neurotoxicity Syndromes; Rats; Rats, Wistar; Response Elements	2009
Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. Journal of neurochemistry, 2009, Volume: 109, Issue:6 Topics: Animals; Clorgyline; Cytosol; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Methamphetamine; Mice; Mice, Inbred C57BL; Microglia; Monoamine Oxidase Inhibitors; Neurons; Neurotoxicity Syndromes; Nucleus Accumbens; Plant Lectins; Reserpine; Ribosome Inactivating Proteins; Time Factors; Tyrosine 3-Monooxygenase	2009
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of neurochemistry, 2010, Volume: 112, Issue:2 Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry	2010
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model. Genesis (New York, N.Y. : 2000), 2011, Volume: 49, Issue:5 Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction	2011
Malnutritional neuropathy under intestinal levodopa infusion. Journal of neural transmission (Vienna, Austria : 1996), 2012, Volume: 119, Issue:3 Topics: Aged; Carbidopa; Humans; Infusions, Parenteral; Levodopa; Male; Malnutrition; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Polyneuropathies	2012
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nature neuroscience, 2011, Dec-18, Volume: 15, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, Transformed; Corpus Striatum; Culture Media, Serum-Free; Disability Evaluation; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Regulation; GTP-Binding Proteins; Humans; Immunosuppressive Agents; Levodopa; Mice; Mice, Knockout; Movement; Mutation; Neurons; Neurotoxicity Syndromes; Oxidopamine; Phosphorylation; Protein Binding; Radioligand Assay; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection	2011
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome	2012
L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology, 2002, Volume: 23, Issue:4-5 Topics: Animals; Antiparkinson Agents; Cell Count; Dopamine Plasma Membrane Transport Proteins; Female; Heterozygote; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Nerve Tissue Proteins; Neuropeptides; Neurotoxicity Syndromes; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins	2002
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. Neuroscience research, 2005, Volume: 51, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances	2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology, 2005, Mar-08, Volume: 64, Issue:5 Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome	2005
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport, 2008, Jan-08, Volume: 19, Issue:1 Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors	2008